Effective immediately,
In addition,
'During the last two years, we have made significant progress in building an R&D team and pipeline, including the development and early approval of TEPEZZA as well as expanding the clinical profile of KRYSTEXXA,' said
About Horizon
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.
Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to anticipated changes in Horizon's R&D team and reporting structure; future results of Horizon's R&D initiatives and business and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks relating to Horizon's ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel and those risks detailed from time-to-time under the caption 'Risk Factors' and elsewhere in Horizon's filings and reports with the
Contact:
Email: media@horizontherapeutics.com
(C) 2020 Electronic News Publishing, source